TABLE 1.
Demographics and baseline characteristics
| Parameter | N = 18 |
|---|---|
| Age, years | 53.6 ± 14.5 |
| Male, n, (%) | 15 (83.3%) |
| BMI (kg/m2) | 24.5 ± 5.2 |
| Smoking n, (%) | 5 (27.8%) |
| Etiology of ESRD n, (%) | |
| Diabetes | 8 (44.4%) |
| Chronic glomerulonephritis | 8 (44.4%) |
| Essential hypertension | 2 (11.1%) |
| Stroke n, (%) | 2 (11.1%) |
| Atrial fibrillation n | 0 |
| Coronary artery disease n, (%) | 2 (5.6%) |
| Duration of dialysis (months) | 36 (16, 69) |
| Antihypertensive drugs n, (%) | |
| Beta‐blocker | 18 (100%) |
| ACEI/ARB | 18 (100%) |
| Calcium channel blocker | 16 (88.9%) |
| Diuretic | 4 (22.2%) |
| sympathetic nervous system inhibitor | 3 (16.7%) |
| Alpha‐blocker | 9 (50%) |
| Vasodilator | 4 (22.2%) |
| Baseline LVEF n, (%) | |
| < 40% | 1 (5.5%) |
| 40–49% | 3 (16.7%) |
| ⩾ 50% | 14 (77.8%) |
| Hemoglobin (g/L) | |
| Week 0 | 104.5 ± 10.4 |
| Week 12 | 106.4 ± 9.2 |
| p value | 0.539 |
| Dry‐weight (kg) | |
| Week 0 | 70.7 ± 17.3 |
| Week 12 | 70.5 ± 16.9 |
| p value | 0.976 |
| spKt/V | |
| Week 0 | 1.22 ± 0.16 |
| Week 12 | 1.24 ± 0.11 |
| p value | 0.612 |
Abbreviations: BMI, body mass index; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF, left ventricular ejection fraction, spKt/V, single pool Kt/V. The results represent the mean the mean ± SEM or medians (P25, P75). P, Week 12 vs. Week 0.